Federated Hermes’s Tempest Therapeutics TPST Stock Holding History

Federated Hermes’s Portfolio TPST Stock Details TPST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Hold	0	–	-$1K	–	2307
2019 Q3	–	Hold	0	–	–	–	2135
2019 Q2	–	Sell	-1	Closed	-$2K	–	2223
2019 Q1	$2K	Hold	1	–	–	﹤0.01%	2072
2018 Q4	$1K	Hold	1	–	–	﹤0.01%	2147
2018 Q3	$2K	Hold	1	–	–	﹤0.01%	2159
2018 Q2	$2K	Hold	1	–	–	﹤0.01%	2116
2018 Q1	$2K	Hold	1	–	–	﹤0.01%	2068
2017 Q4	$3K	Hold	1	–	–	﹤0.01%	2049
2017 Q3	$4K	Hold	1	–	–	﹤0.01%	2002
2017 Q2	$4K	Hold	1	–	–	﹤0.01%	1993
2017 Q1	$5K	Buy	+1	New	+$4.66K	﹤0.01%	1939

Other funds holding TPST

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

Bpifrance Maisons Alfort, Cedex, France $1.65B AUM 19.85% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

AIC

AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Federated Hermes's TPST Position: Q4 2019 in Review

Federated Hermes held its Tempest Therapeutics (TPST) position steady in Q4 2019 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #2307.

Federated Hermes first reported a position in TPST in Q1 2017 and has held it in 9 quarters since. The position peaked at $5K in Q1 2017. 50 funds tracked by Wall St. Rank hold TPST as of Q4 2019.

Federated Hermes held 0 shares of Tempest Therapeutics worth $0 as of Q4 2019.
Federated Hermes left its Tempest Therapeutics share count unchanged in Q4 2019.
Tempest Therapeutics made up ﹤0.01% of Federated Hermes's portfolio in Q4 2019, its #2307 holding.
Federated Hermes first reported a position in Tempest Therapeutics in Q1 2017 and has held it in 9 quarters since.
Federated Hermes's Tempest Therapeutics position peaked at $5K in Q1 2017.
50 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q4 2019.

Based on Federated Hermes's 13F filing for Q4 2019, filed 14 Feb 2020.